Madrigal Pharmaceuticals, Inc. filings document the company’s biopharmaceutical business, commercial reporting for Rezdiffra (resmetirom), and governance matters tied to its Nasdaq-listed common stock. Current reports include quarterly results furnished under Item 2.02, updates on Rezdiffra net sales and cash resources, and Regulation FD disclosures related to pipeline and licensing activity in MASH.
Other filings cover material agreements affecting Rezdiffra intellectual property and royalties, including amendments to a research, development and commercialization agreement, as well as proxy disclosures for director classes, board matters, executive compensation and equity incentive plans. The filing record also documents stockholder meeting proposals and corporate-governance actions for a commercial-stage biopharmaceutical company developing metabolic liver-disease therapies.
Madrigal Pharmaceuticals related party reported proposed sales of common stock under a Form 144 notice. The filing lists a proposed sale of 360 shares tied to a Restricted Stock Unit vesting on 03/06/2026, and discloses prior dispositions of 429 and 263 shares on 01/20/2026 by Shannon Kelley. The broker listed is Morgan Stanley Smith Barney LLC.
Madrigal Pharmaceuticals Chief Commercial Officer Carole Huntsman reported a mix of stock compensation activity and a small tax-related sale. On March 6, 2026, 419 shares of common stock were sold at $431.94 per share to cover tax withholding tied to restricted stock unit vesting; this sale was executed automatically by the company and not at her discretion.
On March 4, 2026, she received 3,989 shares of common stock as a restricted stock unit grant and 4,986 stock options. The restricted stock units vest in four equal annual installments on March 4 of 2027, 2028, 2029 and 2030, contingent on continued service. The stock options vest 25% on March 4, 2027, then 6.25% at the end of each following three‑month period, also subject to continued service.
Carole Huntsman submitted a Form 144 proposing the sale of 419 shares of common stock in Madrigal Pharmaceuticals. The filing lists a Restricted Stock Unit Grant with a 03/06/2026 vesting date tied to 419 shares. The filing also discloses prior sales of 340 and 570 shares on 01/26/2026.
Madrigal Pharmaceuticals director Rebecca Taub reported an automatic sale of common stock tied to tax withholding. On the reported date, 491 shares of Madrigal Pharmaceuticals common stock were sold at an average price of $431.94 per share to cover tax obligations from vesting restricted stock units. After this transaction, Taub directly held 452,213 shares of common stock. She also reported indirect ownership of 655,540 shares held by SQN LLC, where she and her spouse are managing members, while disclaiming beneficial ownership of those shares beyond any pecuniary interest.
Madrigal Pharmaceuticals submitted Rule 144 notices reporting proposed and recent sales of Common Stock by insiders. The filing lists multiple historical sales, including 18,650 shares sold by Rebecca A. Taub on 01/09/2026 and 24,800 shares sold by Paul A. Friedman on 01/09/2026 The excerpt also shows a restricted stock unit vesting of 491 shares on 03/06/2026.
Madrigal Pharmaceuticals Chief Medical Officer David Soergel received new equity awards in the form of stock options and restricted stock units. On March 4, 2026, he was granted options for 5,467 shares at an exercise price of $0.00 per share and 4,374 shares of common stock as a restricted stock unit award.
The restricted stock units vest in four equal installments of 25% on March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, if he remains in service on each date. The option vests 25% on March 4, 2027, with an additional 6.25% vesting on the last day of each successive three‑month period, also subject to continued service. Following these grants, he directly holds 11,919 shares of common stock.
MDGL notice of proposed sale of 1,336 restricted stock units (RSUs) by an issuer-affiliated broker-dealer. The filing lists a trade date of 03/01/2026 and a prior sale of 1,183 common shares on 03/02/2026 reporting proceeds of $505,389.43.
Madrigal Pharmaceuticals EVP and CFO Mardi Dier had 1,183 shares of common stock sold at an average price of $427.21 per share. The shares were sold by the company on her behalf solely to cover tax withholding on vested restricted stock units, in an automatic, non-discretionary transaction. After this sale, she continues to hold 9,257 shares directly.
Madrigal Pharmaceuticals filed a Form 144 disclosing the proposed sale of 1,183 shares of Common Stock in connection with a Restricted Stock Unit grant that vested on 03/02/2026. The filing also reports a prior sale by a 10b5-1 plan of 4,173 shares on 12/02/2025 for $2,413,416.57.
Madrigal Pharmaceuticals director Richard S. Levy exercised stock options for 2,500 shares of common stock. The derivative transaction converted a fully vested stock option into 2,500 common shares at a price of $7.36 per share. Following this exercise, Levy directly owns 27,697 shares of Madrigal common stock.